Muscle Is the New Longevity Drug Target, and the Pipeline Just Got Crowded

[RapAdmin]

Four researchers from Sanford Burnham Prebys and Stanford argue that age-related muscle loss has finally become a tractable drug target. Sarcopenia now has a diagnostic code, a consensus clinical definition, and a mechanistic map spanning mitochondrial failure, blocked autophagy, stem cell exhaustion, nerve withdrawal, chronic inflammation, and vascular decay. The authors survey the therapeutic pipeline built on that map: NAD+ precursors, urolithin A, oleuropein, mTOR inhibitors, myostatin and activin antibodies, selective androgen receptor modulators, apelin and VEGF agonists, and inhibitors of the enzyme 15-PGDH, which the senior author’s laboratory named a “gerozyme.” Their central warning is that gains in muscle mass have repeatedly failed to produce gains in muscle strength, and that the explosion of GLP1 weight loss drugs is now creating sarcopenia risk at population scale.

For most of the last century, losing muscle as you age was treated as scenery rather than pathology. That framing is now gone. Sarcopenia received an ICD-10 code in 2016 and a consensus clinical definition in 2019, and with those two administrative facts came insurance reimbursement, trial endpoints, and pharmaceutical interest. A new review in Nature Reviews Drug Discovery takes stock of what that interest has produced.

The numbers that motivate the field are unforgiving. After 50, people lose roughly 10 percent of their muscle mass per decade. Between 40 and 80, somewhere between 30 and 50 percent of skeletal muscle is gone. Up to one in ten people across 26 surveyed countries meets criteria for sarcopenia. In 2014 the United States spent more than 40 billion dollars on hospitalizations in which nearly half the burden traced back to muscle wasting.

The big idea in the review is that muscle wasting is not one failure but a network of them, and that single-target drugs have kept failing for exactly that reason. Mitochondria in aged muscle swell, lose cristae, leak calcium, and accumulate DNA damage. The mTORC1 pathway is stuck in the “on” position yet somehow fails to build protein, while simultaneously shutting down the cellular recycling that clears damaged mitochondria. Motor neurons retreat from the muscles they once controlled. Muscle stem cell numbers fall by 24 percent in women and 37 percent in men, and two-thirds of the survivors are functionally broken. Fast-twitch fibres, the ones that catch you when you trip, shrink by about 40 percent while slow fibres barely change.

Against that, the authors line up a pipeline. Some entries are supplements already on shelves, including urolithin A, nicotinamide riboside, trigonelline, and the olive polyphenol oleuropein. Some are repurposed drugs, including rapamycin analogues and the arthritis drug tofacitinib. The most commercially advanced are antibodies that block myostatin and activin, which reliably grow muscle in mice and reliably underdeliver in humans.

The authors’ own preferred candidate belongs to a category they invented a word for. A “gerozyme” is an enzyme that becomes more active with age and spends that activity destroying something the body needs. Their example is 15-PGDH, which degrades prostaglandin E2. Force it into young muscle and the muscle ages. Block it in old mice and, according to the review, muscle strength, nerve connections, cartilage, blood, and even the blood-brain barrier improve together. A drug based on this idea has cleared phase I safety testing. The senior author cofounded the company developing it, a disclosure the paper states openly.

The sharpest section concerns GLP1 receptor agonists. Semaglutide and tirzepatide strip 25 to 30 percent of adipose tissue, but lean tissue leaves with it, and when the drug stops, fat returns while muscle does not. With roughly 13 percent of the world living with obesity and a projected billion by 2030, that asymmetry is a public health problem in the making. Several companies are now running combination trials pairing weight loss drugs with muscle-preserving antibodies.

The authors end on an unresolved tension. The field can add muscle. It has not reliably added strength. Until trials measure force and function rather than kilograms, the pipeline’s promise stays theoretical.

Actionable Insights

The single most useful takeaway is a benchmarking one: the review states plainly that exercise plus adequate protein is the standard every drug in this pipeline is measured against, and most drugs lose.

Concrete magnitudes worth knowing:

Myostatin-blocking antibodies, the most advanced muscle drugs in human testing, produce muscle mass gains of 3 to 9 percent with “limited functional improvements.” For a person carrying 28 kg of lean mass, that is roughly 0.8 to 2.5 kg. Supervised resistance training in older adults typically delivers a similar mass change plus large strength gains that the drugs do not match.

Fast-twitch fibres shrink about 40 percent with age while slow fibres are largely spared. Training that only involves walking or steady cardio does not address the fibre type actually being lost. Loaded, explosive, or heavy work does.

If you use a GLP1 receptor agonist, treat muscle preservation as part of the protocol rather than an optional extra. Fat loss of 25 to 30 percent comes with lean tissue loss, and after discontinuation fat returns faster than muscle.

On supplements: human evidence for urolithin A and NAD+ precursors is real but modest, and one mouse experiment in this review found that cutting muscle NAD+ by 85 percent produced no measurable muscle deficit at all.

Context and Source

• Paywalled Paper: Strengthening muscle for healthy ageing: innovative treatments for sarcopenia
• Authors: Sara Ancel, Emmeran Le Moal, Yu Xin Wang, Helen M. Blau (Ancel and Le Moal contributed equally)
• Institutions: Center for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California, USA; Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. Present addresses include Nestlé Institute of Health Sciences (Lausanne, Switzerland) and Regeneron Pharmaceuticals (Tarrytown, New York, USA).
• Country: United States, with Swiss industry affiliation
• Journal: Nature Reviews Drug Discovery
• Publication date: Published online 07 September 2026.
• Article type: Review article, peer reviewed.
• Impact evaluation: The impact score of this journal is 91.2 (2025 Journal Impact Factor, publisher-reported; 5-year JIF 131.3), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

Related Reading:

• The Culprit of Aging - Helen Blau's work at Stanford / PGE2, 15-PDGH
• Longevity Summit 2025 Reporting - Helen Blau PGDH Presentation
• Why Your Fastest, Most Powerful Muscle Fibers Age and Decay First
• BioAge Results for Phase 1b Clinical Trial on Anti Muscle-Aging Drug
• Increasing Muscle Mass in the Elderly
• HIV Drug (Maraviroc) Reverses Muscle Aging by purging “Zombie Cell” Signals

[RapAdmin]

Biomarker Data: Effect Size Extraction

Table 1: Age-related decline (the baseline problem)

Measure	Reported magnitude	Absolute translation
Muscle mass loss after age 50	10 percent per decade	About 27 percent cumulative loss from age 50 to 80
Muscle mass loss, age 40 to 80	30 to 50 percent	For 30 kg lean mass at 40, a loss of 9 to 15 kg
Type II (fast-twitch) fibre size	40 percent reduction	Type I fibres largely unchanged, so the loss is concentrated
Muscle stem cell number	Down 24 percent (women), 37 percent (men)	Plus two-thirds of survivors functionally impaired
Testosterone, men after 30	Approximately 1 percent per year	About 26 percent cumulative by 60, 39 percent by 80
IGF1	About 50 percent lower by age 60	Halved
Muscle NAD+	About 50 percent decline in aged mice	Human decline described as “more subtle,” unquantified
Sarcopenia prevalence	Up to 10 percent across 26 countries	1 in 10

Table 2: Intervention effects, as reported

Intervention	Model	Reported effect	Effect size interpretation
Trevogrumab (anti-myostatin, Regeneron)	Aged mice	Gastrocnemius weight up 19 to 25 percent, improved treadmill performance	Large in relative terms. Preclinical mouse muscle mass measurements typically carry a coefficient of variation near 5 to 8 percent, which if assumed would put d in the range of roughly 2.5 to 5. This is an assumption, not a reported value. [Confidence: Low on the d estimate, High on the 19 to 25 percent figure]
Bimagrumab, LY2495655 (anti-myostatin pathway)	Humans	Muscle mass gains of 3 to 9 percent, “limited functional improvements”	The gap between mass and function is the finding. A 3 to 9 percent lean mass gain is roughly 0.8 to 2.5 kg on a 28 kg lean baseline. Functional endpoints did not follow. [Confidence: High]
AKT-mTORC1 activation	Mouse myofibre	Doubling of myofibre size	100 percent increase, but this is a genetic manipulation, not a drug effect
GLP1RA (semaglutide, tirzepatide)	Humans	25 to 30 percent adipose tissue loss, accompanied by lean mass loss	Lean mass loss fraction not quantified in the review. On discontinuation, fat is “rapidly regained but muscle is not.” Asymmetric and clinically important. [Confidence: High for direction, Low for magnitude]
MF-300 (15-PGDH inhibitor, Epirium Bio)	Aged mice	Increased strength and specific force after 12 weeks; dose-dependent effect on plantar flexor force in SMA model	No numerical effect size given. Phase I safety established, phase IIb planned. Note the commercial disclosure above. [Confidence: Low on magnitude]
RAD001 (everolimus analogue, 0.1 mg daily, 6 weeks)	Older humans	Decreased infection rates	Immune endpoint, not a muscle endpoint. Frequently misquoted as a muscle result
Enobosarm (SARM)	Older adults, 12 weeks	Increased lean body mass and stair climb performance	Duration too short for a chronic condition. No magnitude given
MK-0773 (SARM)	Older women, 6 months	Lean mass improved, strength did not	Same mass-without-function dissociation
Growth hormone	Meta-analysis, 306 GH-deficient patients	Gains in aerobic capacity and muscle mass	A subsequent review of nine trials did not confirm strength benefit. The population was GH-deficient, not sarcopenic, which limits transfer [Confidence: High]
Tofacitinib (JAK inhibitor)	Isolated human myofibres, 48 hours	Increased contractile force	Ex vivo only. No organism-level evidence
Nicotinamide riboside	Older humans	“Limited improvements” in one set of studies, “no benefit” on regeneration after eccentric injury in another	Effectively null in the review’s own summary [Confidence: High]
Muscle-specific NAMPT knockout	Adult mice	85 percent reduction in muscle NAD+, no adverse effect on glycaemic control, energetics, exercise capacity, or fibre size	This is a falsification signal against the simple NAD+ depletion model of sarcopenia. An 85 percent depletion producing no phenotype is a large null [Confidence: High]
Azelaprag (apelin agonist) plus tirzepatide	Phase II, STRIDES	Discontinued for liver transaminitis	Safety failure, not efficacy failure

The single most important pattern in this table: interventions that increase muscle mass in humans do so at 3 to 9 percent, and in trial after trial the functional endpoint does not move with the mass endpoint. The review states this directly in its conclusion: “gains in muscle mass often do not translate to gains in strength.” That sentence is the honest centre of the paper.

[RobTuck]

The SD on some of these metrics has to be large. I was in my late 60’s before some of my weight bearing and aerobic performance dropped significantly. Before that, most of the y/y decline was slight and could be offset in the increment with increased training.

Most interesting to me in this line of thought – unfortunately all N=1 observations – at least one the muscle groups that I may have used most and pushed the hardest in the decades of what now seems like extreme running, cycling, and walking have virtually fully retained their instantaneous strength while the others (most of them) have declined significantly in spite of my best efforts. The calf raise machines. My current gym is very well equipped, including three different calf machines (think toe raises, broadly). I have been familiar with two of the three for decades; one is a new design. Most have an effective lift weight of 300 to 420 pounds, occasionally more. When I was in my 40’s none of the plates on any of the machines were heavy enough to push me down to 1-RM or even 3-RM. Now, in my 80s, that is still the case. I am easily calf pressing 100+ more pounds than anyone I see in the gym and 250 more than typical gym rats my age. This is not personal self-congratulation. It feels good, of course, but it seems like clear evidence of long term muscle restructuring that may not yet be fully understood.